keyword
MENU ▼
Read by QxMD icon Read
search

Ribavirin

keyword
https://www.readbyqxmd.com/read/28088273/a-real-world-impact-of-cost-effectiveness-of-pegylated-interferon-ribavarin-regimens-on-treatment-na%C3%A3-ve-chronic-hepatitis-c-patients-in-taiwan
#1
Pei-Chien Tsai, Ta-Wei Liu, Meng-Hsuan Hsieh, Ming-Lun Yeh, Po-Cheng Liang, Yi-Hung Lin, Ching-I Huang, Chung-Feng Huang, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Treatments with pegylated interferon/ribavirin (PEG-IFN/RBV) has been standard-of-care in patients with chronic hepatitis C virus (HCV) (CHC) infection and reimbursed in Taiwan. However, the actual cost-effectiveness remains unclear. We aimed to evaluate a real-world cost-effectiveness for CHC patients treated with PEG-IFN/RBV by using a clinical cohort with linkage to the National Health Insurance Research Database of Taiwan. The total and itemized medical-care expenses of outpatient visits of 117 treatment-naïve CHC patients with linkage to the two million sampling of the National Health Insurance Research Database were collected...
January 2017: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/28081594/management-of-direct-antiviral-agent-failures
#2
REVIEW
María Buti, Rafael Esteban
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve viral elimination, but 1% to 15% fail to attain this objective. Treatment failures are usually related to relapse, and less often to on-treatment viral breakthrough. HCV drug resistant associated substitutions are detected in most patients who do not eliminate the virus. The risk of developing these variants depends on host- and virus-related factors, the properties of the drugs used, and the treatment strategies applied...
December 2016: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28078644/eight-or-12-week-treatment-of-hepatitis-c-with-ledipasvir-sofosbuvir-real-world-experience-in-a-large-integrated-health-system
#3
Jennifer B Lai, Maxwell A Witt, Mary Patricia Pauly, Joanna Ready, Michael Allerton, Suk Seo, David J Witt
BACKGROUND: Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of ledipasvir/sofosbuvir (LDV/SOF) have been supported in some studies, but data are limited on efficacy in real-world use. Controversy exists regarding applicability of clinical trials to real-world effectiveness. We report virologic responses of patients with HCV genotype 1 infection receiving LDV/SOF for 8 or 12 weeks in a large integrated healthcare system...
January 11, 2017: Drugs
https://www.readbyqxmd.com/read/28077243/effective-use-of-oral-ribavirin-for-respiratory-syncytial-viral-infections-in-allogeneic-haematopoietic-stem-cell-transplant-recipients
#4
C M Gorcea, E Tholouli, A Turner, M Saif, E Davies, E Battersby, F L Dignan
BACKGROUND: Respiratory syncytial virus (RSV) is a frequent cause of respiratory viral infections, increasing the morbidity and mortality in allogeneic haematopoietic stem cell transplantation (HSCT) recipients. Little is known about the best management strategy in this immunocompromised group and there are very few data on oral ribavirin treatment. AIM: To evaluate the effectiveness of oral ribavirin in allogeneic HSCT patients with RSV infection. METHODS: Twenty-three RSV cases treated with oral ribavirin were analysed retrospectively...
November 25, 2016: Journal of Hospital Infection
https://www.readbyqxmd.com/read/28072888/clinical-and-virological-predictors-of-sustained-response-with-an-interferon-based-simeprevir-regimen-for-patients-with-chronic-genotype-1-hepatitis-c-virus-infection
#5
Gianpiero D'Offizi, Calogero Cammà, Chiara Taibi, Michael Schlag, Karin Weber, Maria Palma, Ralph DeMasi, Katrien Janssen, James Witek, Raffaella Lionetti
Simeprevir plus peg-interferon/ribavirin (PR) is approved to treat chronic hepatitis C (HCV) genotype 1 (GT1) and GT4 infection. This study aimed to assess baseline and on-treatment the factors predictive of sustained virologic response 12 weeks post-treatment (SVR12) in patients receiving 12 weeks of simeprevir plus PR followed by 12 or 36 weeks of PR. Data from participants in four studies (QUEST-1, QUEST-2, ATTAIN and PROMISE) were pooled to examine the efficacy and safety of simeprevir+PR in HCV GT1 patients...
January 9, 2017: New Microbiologica
https://www.readbyqxmd.com/read/28072684/assessment-of-hepatocellular-carcinoma-risk-based-on-peg-interferon-plus-ribavirin-treatment-experience-in-this-new-era-of-highly-effective-oral-antiviral-drugs
#6
Seung Ho Lee, Young-Joo Jin, Jun Young Shin, Jin-Woo Lee
In this new era of highly effective oral antiviral drugs for chronic hepatitis C virus (HCV), indications for antiviral treatment may be extendable. This study undertaken to identify suitable candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma (HCC) risk in patients with chronic HCV treated or not with PEG-IFN/RBV.This large-scale retrospective study was conducted on 1176 patients with chronic HCV without a history of HCC (treatment group [n = 489] and no-treatment group [n = 687])...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28070899/sofosbuvir-based-treatment-regimens-real-life-results-of-14-409-chronic-hcv-genotype-4-patients-in-egypt
#7
A Elsharkawy, R Fouad, W El Akel, M El Raziky, M Hassany, G Shiha, M Said, I Motawea, T El Demerdash, S Seif, A Gaballah, Y El Shazly, M A M Makhlouf, I Waked, A O Abdelaziz, A Yosry, M El Serafy, M Thursz, W Doss, G Esmat
BACKGROUND: Chronic hepatitis C virus infection is one of the most important health problems in Egypt. The Ministry of Health's National Treatment Programme introduced sofosbuvir-based therapy in October 2014. AIM: To assess the clinical effectiveness and predictors of response to SOF-based treatment regimens, either dual therapy, with SOF/ribavirin (RBV) for 6 months or triple therapy with SOF/peg-IFN-alfa-2a/RBV for 3 months, in a cohort of patients treated in National Treatment Programme affiliated centres in Egypt...
January 9, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28070200/the-risk-of-hepatocellular-carcinoma-after-directly-acting-antivirals-for-hepatitis-c-virus-treatment-in-liver-transplanted-patients-is-it-real
#8
Alessio Strazzulla, Rosa Maria Rita Iemmolo, Ennio Carbone, Maria Concetta Postorino, Maria Mazzitelli, Mario De Santis, Fabrizio Di Benedetto, Costanza Maria Cristiani, Chiara Costa, Vincenzo Pisani, Carlo Torti
INTRODUCTION: Since directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) were introduced, conflicting data emerged about the risk of hepatocellular carcinoma (HCC) after interferon (IFN)-free treatments. We present a case of recurrent, extra-hepatic HCC in a liver-transplanted patient soon after successful treatment with DAAs, along with a short review of literature. CASE PRESENTATION: In 2010, a 53-year old man, affected by chronic HCV (genotype 1) infection and decompensated cirrhosis, underwent liver resection for HCC and subsequently received orthotopic liver transplantation...
November 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/28070175/a-special-meeting-review-edition-advances-in-the-treatment-of-hepatitis-c-virus-infection-from-the-2016-easl-meeting-the-annual-meeting-of-the-european-association-for-the-study-of-the-liver-%C3%A2-april-13-17-2016-%C3%A2-barcelona-spainspecial-reporting-on-%C3%A2-six-weeks
#9
https://www.readbyqxmd.com/read/28070174/the-hcv-treatment-revolution-continues-resistance-considerations-pangenotypic-efficacy-and-advances-in-challenging-populations
#10
Ira M Jacobson
The US Food and Drug Administration has now approved 10 direct-acting antivirals (DAAs) for the management of hepatitis C virus (HCV). These therapies are combined into 6 regimens that are given for varying durations, with or without ribavirin, depending on the viral genotype, the presence or absence of baseline resistance-associated variants (RAVs), and the patient type. RAVs may be present before exposure to a drug or may become detectable de novo during exposure to a drug. Emerging resistant strains are the most common cause of failure of HCV DAA regimens...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28069471/an-unexpected-fatal-cchf-case-and-management-of-exposed-health-care-workers
#11
Goksel Guven, Leyla Talan, Neriman Defne Altintaş, Kemal Osman Memikoglu, Fugen Yoruk, Alpay Azap
Crimean-Congo hemorrhagic fever (CCHF) is a tick borne viral disease which can also be transmitted by direct contact with blood or tissue specimens of infected animals or humans. We present a fatal case of CCHF, who was diagnosed after death, and describe the post-exposure management plan for the health care workers (HCWs) involved in her care. In total of 52 HCWs were involved in the patient's care and they were stratified into risk groups. Overall, 20 HCWs were grouped in high and intermediate risk groups, including the HCW with needle stick injury...
January 6, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28065255/a-54-year-old-man-with-lingual-granuloma-and-multiple-pulmonary-excavated-nodules
#12
Julien Dang, Noémie Chanson, Caroline Charlier, Christine Bonnal, Gregory Jouvion, Tiphaine Goulenok, Thomas Papo, Karim Sacre
A 54-year-old French man was admitted for evaluation of a chronic nodular lesion of the tongue and mandibular lymphadenopathy. He reported active tobacco and cannabis smoking as well as excessive alcohol use. He also reported frequent use of cocaine for several months and a past addiction to IV heroin. He had traveled abroad as a journalist and lived for several months in Columbia and Venezuela 12 years ago. His medical history included chronic hepatitis C infection successfully treated with interferon and ribavirin 6 years ago and high BP...
January 2017: Chest
https://www.readbyqxmd.com/read/28063412/spectral-characterisation-antiviral-activities-in-silico-admet-and-molecular-docking-of-the-compounds-isolated-from-tectona-grandis-to-chikungunya-virus
#13
Sangeetha K, Indu Purushothaman, Rajarajan S
Chikungunya infection is treated symptomatically with antipyretics and anti-inflammatory drugs without any specific antiviral drug till date. The lack of an approved antiviral drug and the emergence of virulent strains after 2006 epidemics emphasize the need for the development of potential antiviral drugs to Chikungunya virus. Hence, we studied the antiviral activity of the extracts and compounds isolated from Tectona grandis leaves to both the Asian and East central South African strains of Chikungunya virus...
January 4, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28061762/the-effectiveness-of-daclatasvir-based-therapy-in-european-patients-with-chronic-hepatitis-c-and-advanced-liver-disease
#14
Jim Young, Nina Weis, Harald Hofer, William Irving, Ola Weiland, Emiliano Giostra, Juan Manuel Pascasio, Lluis Castells, Martin Prieto, Roelien Postema, Cinira Lefevre, David Evans, Heiner C Bucher, Jose Luis Calleja
BACKGROUND: There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options. METHODS: A retrospective multi-country cohort of patients with chronic hepatitis C who received daclatasvir as part of the Named Patient Program in Austria, Denmark, Spain, Sweden, Switzerland and the United Kingdom...
January 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28060446/successful-treatment-of-donor-derived-hepatitis-c-viral-infection-in-three-transplant-recipients-from-a-donor-at-increased-risk-for-bloodborne-pathogens
#15
Ashesh P Shah, Andrew Cameron, Pooja Singh, Adam M Frank, Jonathan M Fenkel
We report here the successful treatment of hepatitis C virus (HCV) transmitted from a nucleic acid testing (NAT)-negative donor to 3 HCV-negative recipients - 2 renal transplants and 1 liver. Both renal recipients underwent standard deceased-donor renal transplantation with immediate graft function. The liver recipient underwent standard orthotopic liver transplantation and recovered uneventfully. The donor was a 39-year-old woman with a terminal serum creatinine of 0.7 mg/dL. She was high risk for bloodborne pathogens, based upon a history of sexual contact with an HCV-infected male partner...
January 6, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28058039/assessment-of-il-28-rs12979860-and-rs8099917-polymorphisms-in-a-cohort-of-cuban-chronic-hcv-genotype-1b-patients
#16
Daniel Palenzuela Gardón, Isabel Alicia Guillen, Julio R Fernández, Hamlet Camacho, Zurina Cinza Estevez, Santiago Dueñas, Liz Alvares-Lajonchere, Yalena Amador, Gillian Martinez-Donato, Junsong Han, Zhiming Zhang, Xiaona Zhang, Yang Gao, Juan Roca Campaña, Lidia I Novoa
Hepatitis C virus (HCV) is a significant global public health problem with >185 million infections worldwide. A series of genome-wide association studies (GWAS) has identified IL-28B polymorphisms as a predictor of sustained virologic response (SVR), as well as spontaneous clearance in chronic HCV genotype 1 patients. The objective of this work was to evaluate the prevalence of IL-28B rs12979860 and rs8099917 polymorphisms in Cuban chronic HCV patients. The study cohort included 73 chronic HCV patients treated with concomitant administration of CIGB-230 and nonpegylated IFN-α plus ribavirin (non-pegIFN-α/R) antiviral therapy...
December 16, 2016: Journal of Biomolecular Techniques: JBT
https://www.readbyqxmd.com/read/28056030/efficacy-of-a-12-week-simeprevir-plus-peginterferon-ribavirin-pr-regimen-in-treatment-na%C3%A3-ve-patients-with-hepatitis-c-virus-hcv-genotype-4-gt4-infection-and-mild-to-moderate-fibrosis-displaying-early-on-treatment-virologic-response
#17
Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Faisal Sanai, Ceyhun Bicer, Oliver Lenz, Gino Van Dooren, Catherine Nalpas, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti
BACKGROUND: HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treatment (SVR12). Additional objectives included investigation of potential associations of rapid virologic response and baseline factors with SVR12...
2017: PloS One
https://www.readbyqxmd.com/read/28054734/compassionate-use-experience-with-high-titer-respiratory-syncytical-virus-rsv-immunoglobulin-in-rsv-infected-immunocompromised-persons
#18
Ann R Falsey, Christine Koval, John P DeVincenzo, Edward E Walsh
BACKGROUND: Respiratory syncytial virus (RSV) may cause fatal lower respiratory tract infection (LRTI) in immunocompromised patients. Ribavirin with or without standard intravenous immunoglobulin (IVIG) is frequently given although efficacy is debated. Infusion of IVIG with high levels of neutralizing antibody against RSV may offer benefit in these patients. METHODS: RI-001 contains standardized levels of high-titer anti-RSV neutralizing antibody and was provided for compassionate use to 15 patients with RSV LRTI who either failed conventional therapy or had significant risk of progression...
January 5, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28053847/evaluation-of-antiviral-activity-of-zanthoxylum-species-against-picornaviruses
#19
Hwa-Jung Choi
Human rhinoviruses and enteroviruses (family Picornaviridae) infect millions of people worldwide each year, but little is known about effective therapeutical treatment for the infection caused by these viruses. We sought to determine whether or not Zanthoxylum (Rutaceae) species can exhibit antiviral activity against picornaviruses. The leaf parts of four Zanthoxylum species were extracted with methanol, and the extracts were investigated for their antiviral activity against picornaviruses using cytopathic effects by cytopathic effect reduction...
December 2016: Osong Public Health and Research Perspectives
https://www.readbyqxmd.com/read/28053102/5-phospho-rna-acceptor-specificity-of-gdp-polyribonucleotidyltransferase-of-vesicular-stomatitis-virus-in-mrna-capping
#20
Minako Ogino, Tomoaki Ogino
: The GDP polyribonucleotidyltransferase (PRNTase) domain of the multifunctional L protein of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus, catalyzes the transfer of 5' -phospho-RNA (pRNA) from 5' -triphospho-RNA (pppRNA) to GDP via a covalent enzyme-pRNA intermediate to generate a 5' -cap structure (GpppA). Here, using an improved oligo-RNA capping assay with the VSV L protein, we showed that the Michaelis constants for GDP and pppAACAG (VSV mRNA-start sequence) are 0...
January 4, 2017: Journal of Virology
keyword
keyword
29712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"